No Data
No Data
Shanghai Shen Lian Biomedical Corporation (stock code 688098.SH) plans to distribute 0.035 yuan per share in 2023, with the ex-rights and ex-dividend date on June 14.
Shanghai Shen Lian Biomedical Corporation (688098.SH) announced that it plans to distribute a cash dividend of ¥0.035 per share (including tax) for the year 2023. The registration date is June 13, 2024, and the ex-dividend date is June 14, 2024.
Shenlian Biology (688098.SH): At present, it has accumulated synthetic biotechnology based on yeast strains, etc.
Gelonghui, May 8, 丨 Shenlian Biology (688098.SH) said on the interactive platform that the company has now accumulated synthetic biotechnology based on yeast strains, etc., and related platforms are in the process of development and construction, and no related products have yet been produced.
Shenlian Biotech (688098.SH): Swine Fever Vaccine Approved for New Veterinary Drug Registration
On May 5, Ge Longhui Biotech (688098.SH) issued a notice to approve the company's swine fever genetically-engineered subunit vaccine (CHO-133D) as a new veterinary drug and issued a “New Veterinary Drug Registration Certificate” after review by the Ministry of Agriculture and Rural Affairs of China in accordance with the “Veterinary Drug Administration Regulations” and the “Veterinary Drug Registration Measures”.
Weak Statutory Earnings May Not Tell The Whole Story For Shanghai Shen Lian Biomedical (SHSE:688098)
Shenlian Biotech (688098.SH): Net loss of 2.09 million yuan in the first quarter
Gelonghui, April 26 | Shenlian Biotech (688098.SH) released its first quarter report. Operating revenue was 880.58 million yuan, up 7.58% year on year, with a net loss of 2.209 million yuan, after deducting non-net loss of 2.889 million yuan, and basic earnings per share of -0.01 yuan.
Weak Financial Prospects Seem To Be Dragging Down Shanghai Shen Lian Biomedical Corporation (SHSE:688098) Stock
No Data